Orphan drug grants
Executive Summary
FDA will award about 15 grants ranging from $20,000 to $100,000 in direct costs for up to three years to support clinical trials, according to an announcement in the Oct. 26 edition of the Federal Register. While some preliminary clinical research should already be available, the agency will consider drugs for which "persuasive pharmacologic evidence is available that a product has a reasonable possibility of being effective even though no clinical trials have been performed." Applications, which should be "for one discrete clinical trial," must be received by Jan. 25, 1988, with the earliest beginning date for awards July 1.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.